Lantern Pharma (NASDAQ: LTRN) has announced the establishment of the AI Center of Excellence and Advanced Agentic Labs in Bengaluru, India, to industrialize its proprietary RADR AI platform, which integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials.
According to Lantern, this strategic initiative represents a critical inflection point in Lantern’s evolution—transitioning from pioneering AI-enabled drug discovery in cancer to industrializing those capabilities at global scale for the broader drug development community.
In a statement, Panna Sharma, president and CEO of Lantern, commented, “Lantern was founded on the conviction that artificial intelligence and data-driven methodologies can fundamentally redefine drug discovery paradigms. Our AI Center of Excellence represents the industrialization of that vision—scaling proven RADR capabilities to serve the growing number of pharmaceutical partners seeking precision, data-guided therapies across oncology and beyond with increasingly more aggressive timelines. This initiative strategically positions Lantern at the forefront of the pharmaceutical industry’s transformation from computational experimentation to systematic, AI-powered therapeutic development that addresses critical unmet patient needs globally. Our approach simultaneously plays a central role in containing development costs and increasing R&D efficiency.”
